DVA - Educational Analysis * US Equities
Educational Analysis * US Equities

DVA

Earnings behavior, post-earnings drift, and the gap between consensus and the market's real expectation - the educational primer before you look at the institutional verdict.

Educational content only - not investment advice. Nothing on this page is a recommendation to buy or sell any security. Historical patterns do not predict future outcomes. Consult a licensed financial advisor before making any trading decision.
Published byGamma QC editorial
TickerDVA
CategoryEducational primer
Last reviewedNovember 16, 2026
You're viewing an older edition of this page.Read the latest edition →

Business profile & competitive position

DaVita Inc. operates within the Healthcare sector, specifically the Medical - Care Facilities industry, as a leading United States provider of kidney dialysis services and related laboratory services for patients with chronic kidney failure and end-stage kidney disease. As of December 31, 2025, the company ran 2,657 outpatient U.S. dialysis centers serving approximately 200,500 patients. It also maintains international operations spanning 585 outpatient dialysis centers across 14 countries and approximately 94,500 patients, plus integrated kidney care, ancillary services, hospital inpatient dialysis, home-based dialysis, and transplant support.

The financial posture offers a mixed signal on competitive moat. The net margin of 6.5% is modest for a healthcare services business, suggesting DaVita earns thin profitability per dollar of revenue despite its scale. More striking is the ROE of -133.2%, which indicates shareholder equity has turned negative, typically the result of accumulated share buybacks or liabilities exceeding assets rather than operational losses alone. A large, negative ROE in a capital-intensive facility network is not uncommon when leverage is high, but it also means book equity is not the source of returns. The beta of 0.86 implies the stock has historically moved slightly less than the overall market, consistent with a services business tied to recurring patient volumes and government reimbursement rather than cyclical demand.

Financial posture

At the time of this snapshot, DaVita carried an $11.0 billion market capitalization and traded at a P/E ratio of 13.4. That valuation sits below the typical multiples seen in broader healthcare services, which can reflect both the reimbursement-policy risk embedded in dialysis economics and the company's leveraged balance sheet. The 6.5% net margin leaves limited room for pricing pressure from Medicare, Medicaid, or commercial insurers. The negative ROE of -133.2% underscores that returns are being generated on a diminished or negative equity base, a posture that can magnify both upside and downside for shareholders.

The stock price was $174.11, with a 50-day EMA of $184.61 and an RSI of 43.8, placing the shares below the near-term moving average but not in technically oversold territory. These figures are descriptive only and do not imply a directional call.

Strategic priorities & outlook

According to DaVita's most recent SEC 10-K filing, the company's operational focus centers on reimagining kidney care to become more preventative, better integrated, outcome-focused, lower-cost, and personalized at scale. It is building integrated care capabilities across the renal continuum, from chronic kidney disease through end-stage kidney disease to kidney transplant. A specific reimbursement anchor is the Comprehensive Kidney Care Contracting model, whose goals include delaying disease progression, promoting home dialysis when clinically appropriate, and incentivizing transplants.

Operationally, the filing notes that U.S. dialysis revenues represented approximately 86% of consolidated revenues, and nearly all non-hospital dialysis profits came from commercial payors. That concentration means pricing negotiated with commercial insurers is disproportionately important to profitability. DaVita also highlights quality credentials, having led CMS's Quality Incentive Program for 11 of the most recently reported years and the Five-Star Quality Rating System for 10 of the most recently reported years.

Macro & geopolitical exposure

As a Medical - Care Facilities company, DaVita is primarily exposed to U.S. healthcare regulation, reimbursement policy, and demographic trends rather than broad commodity or currency cycles. Dialysis is heavily reimbursed by government programs, so changes to Medicare payment rates, the Comprehensive Kidney Care Contracting model, or Medicaid funding directly affect revenue. The industry also faces regulatory scrutiny around staffing ratios, infection control, and quality metrics.

Trade policy and foreign currency are secondary but real considerations given the international footprint across 14 countries; exchange-rate swings can affect translated earnings. Supply-chain exposure is present for dialysis machines, concentrates, and pharmaceuticals, though much of the business is service-based and local. Litigation and antitrust risk are recurring features for large dialysis networks given their market concentration and contracting practices with physicians and insurers.

Recent developments

Recent news has carried both operating and legal overtones. On November 13, 2026, MarketBeat reported that DaVita expects fewer dialysis treatments in the fourth quarter but that higher revenue per visit could help offset the volume drop. That tension between volume softness and pricing uplift is a central issue for investors heading into the next reporting cycle.

On November 12, 2026, three separate legal-related items appeared. BusinessWire noted that investors have an opportunity to join a DaVita fraud investigation with SBS Law. Benzinga reported that dialysis giants DaVita and Fresenius are accused in a Washington lawsuit of blocking competition. GuruFocus carried an investor alert that Pomerantz Law Firm is investigating claims on behalf of DaVita investors. These items do not establish wrongdoing, but they illustrate the elevated litigation and regulatory scrutiny that can accompany the dialysis-provider business model.

Earnings behavior & post-earnings drift

DaVita's recent earnings record is strong on the headline beat rate but more complicated in price reaction. Over the last eight reported quarters, the company beat the market's real expectation in seven of them, an 88% beat rate, with an average earnings surprise of 3.8%. The average five-day price move following those reports was 7.62% to the upside, classifying the post-earnings drift as "up."

Yet the last four quarters show a wide range of outcomes. The October 29, 2026 report delivered $3.82 versus an estimate of $3.57, a 7.0% surprise, but the stock fell 3.01% the next day and only recovered to a 0.78% gain over the following five days. The August 4, 2026 beat of $4.02 versus $3.88, a 3.6% surprise, was followed by a 17.24% single-day drop and a 21.78% decline over five days, suggesting the market's real expectation or forward guidance disappointed despite the beat. In contrast, the May 5, 2026 report of $2.87 versus $2.41, a 19.1% surprise, produced a 23.46% one-day gain and a 27.7% five-day drift. The February 2, 2026 result of $3.40 versus $3.24, a 4.9% surprise, was followed by a 21.17% next-day rally and a 23.79% five-day drift.

The next scheduled earnings release is February 1, 2027, after the close, with a consensus EPS estimate of $4.14. The uneven price reaction pattern suggests that meeting or beating the estimate does not, by itself, guarantee a positive market response; guidance, volume trends, and commercial pricing commentary appear to drive the post-report move.

For a deeper dive into how institutional analysts are interpreting DaVita's reimbursement risk, legal exposure, and earnings setup, readers should review the full institutional verdict on the ticker.

Frequently Asked Questions

What does DaVita actually do?

DaVita is a U.S.-focused kidney dialysis provider operating 2,657 outpatient U.S. centers and serving about 200,500 patients as of December 31, 2025. It also runs international dialysis centers, integrated kidney care services, and support for home dialysis and transplants.

Why is DaVita's ROE negative?

The ROE is -133.2% because shareholder equity is negative, typically reflecting a leveraged balance sheet and substantial share buybacks rather than a single-quarter operating loss. It means returns are being generated on a thin or negative equity base.

How has DaVita stock reacted after recent earnings?

Over the last eight quarters it has beaten the unofficial consensus 88% of the time with an average surprise of 3.8% and an average five-day post-earnings drift of 7.62% up. However, the two most recent reports saw muted or negative price reactions despite EPS beats.

Real Data - Gamma QC Earnings IntelligenceAs of Nov 16, 2026
DaVita Inc. · Healthcare / Medical - Care Facilities
$11.0BMarket cap
13.4P/E
6.5%Net margin
-133.2%ROE
88%Beat rate, last 8Q
3.8%Avg EPS surprise
7.62%Avg 5-day move after earnings
2027-02-01Next earnings
ReportedActualEstimateSurprise1D Move5D Move
2026-10-29$3.82$3.57+7%-3.01%+0.78%
2026-08-04$4.02$3.88+3.6%-17.24%-21.78%
2026-05-05$2.87$2.41+19.1%+23.46%+27.7%
2026-02-02$3.4$3.24+4.9%+21.17%+23.79%
2025-10-29$2.51$3.17-20.8%--
2025-08-05$2.95$2.7+9.3%--

Previous DVA editions

Beyond the primer

Get the institutional verdict on DVA

Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.

Read the DVA verdict at Gamma QC
$49 Pro / $249 RIA * gammaqc.com

Verify authenticity

Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.